METHODS: Ninty-two patients who underwent RP between 2004 and 2009 had venous blood samples taken pre- (Day - 1) and post-operatively (Day + 7). We performed quantitative Taqman® RT-PCR to detect circulating prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) mRNA. We calculated both the logarithmic ratio of Day + 7/Day - 1 for PSA (PSAr) and PSMA (PSMAr) expression (logDay+7/Day-1 ) and the Kattan nomogram predicted probability of disease recurrence for each patient. We then analyzed how the AUC-ROC analysis for the Kattan nomogram prediction alone (K) compared to the addition of the PSAr and PSMAr in predicting 5-year RFS.
RESULTS: The mean age (years), PSA (ng/ml), and follow-up (mo) was 65.1, 9.13, and 72, respectively. The AUCs for K, PSAr + K, and PSMAr + K were 0.752 (95%CI 0.620-0.860), 0.830 (95%CI 0.740-0.911), and 0.837 (95%CI 0.613-0.923), respectively (P = 0.03). The Kattan 5-year PSA RFS was 75%. The actual 5-year PSA RFS survival rate was 77%.
CONCLUSIONS: Data from modern quantitative RT-PCR to detect circulating prostate-derived PSA and PSM mRNA pre- and post-RP improves the accuracy of the Kattan nomogram to predict biochemical recurrence.
Written by:
Yates DR, Rouprêt M, Drouin SJ, Comperat E, Ricci S, Lacave R, Sèbe P, Cancel-Tassin G, Bitker MO, Cussenot O. Are you the author?
Faculté de Médecine Pierre et Marie Curie, Academic Department of Urology of la Pitie Salpetriere Hospital, Assistance Publique-Hôpitaux de Paris, University Paris VI, Paris, France.
Reference: Prostate. 2012 Jan 6. Epub ahead of print.
doi: 10.1002/pros.22488
PubMed Abstract
PMID: 22228175
UroToday.com Prostate Cancer Section